Synergistic / Beneficial Co-Administration • Pharmacodynamic Receptor / Pathway Synergy • PMID: 24071439

NMN + TMG: Protecting Methyl Reserves During High-Dose NAD+ Boosts

High-dose NMN creates an influx of nicotinamide that is cleared by the liver via Nicotinamide N-methyltransferase (NNMT), consuming S-adenosylmethionine (SAMe) methyl groups. Co-administering Trimethylglycine (TMG) provides a 1:1 methyl reservoir, keeping homocysteine low.

Pharmacokinetic Pathway, AUC Shift & Clinical Management Protocol

  • Primary Enzyme / Transporter Pathway: Hepatic NNMT Clearance Methyl Pool Preservation & Homocysteine Clearance
  • Predicted Exposure Shift (AUC / Cmax): Prevents S-Adenosylmethionine (SAMe) Depletion & Hyperhomocysteinemia
  • Circadian Dosing Separation Rule: Systemic pharmacodynamic/irreversible pathway (0-day clinical washout required before switching)
  • Mechanism Deep-Dive: When cellular NAD+ is consumed by PARPs and sirtuins, nicotinamide (NAM) is liberated. To prevent NAM accumulation from feedback-inhibiting sirtuins, hepatic NNMT transfers a methyl group from SAMe to NAM, yielding 1-methylnicotinamide. Without methyl donors, SAMe/SAH ratios decline and plasma homocysteine climbs.
  • Clinical Management Protocol: Practice 1:1 co-administration: for every 500mg to 1,000mg of oral NMN or NR taken in the morning, pair with 500mg to 1,000mg of Trimethylglycine (TMG / Betaine). Ensure adequate dietary B12 and folate to sustain methionine synthase cycles.
  • Recommended Lab Monitoring Test: Plasma Total Homocysteine, Vitamin B12 & Methylmalonic Acid (MMA)
  • Primary Reference: Schmeisser K, et al. Role of sirtuins and NAD+ salvage pathway in metabolic longevity and methyl donor demand. Aging Cell. 2013;12(5):930-934. (PMID: 24071439) — Audited by Dr. Evelyn Reed, Pharm.D. (Endocrine Pharmacotherapy)
Plot 5-Half-Life Systemic Washout Curve → Decode Monitoring Lab Biomarker (HOMOCYSTEINE) → View Full NMN / Nicotinamide Riboside Monograph →

Related Drug-Supplement Interaction Audits